Rand,multicenter,DB,placebo-controlled,parallel-group phase III study to investigate the efficacy, safety and tolerability of 2 diff doses of IgPro20(subcutaneious,Ig) for the treatment of chronic inflammatory demyelinating polyneuropathy(CIDP)